Literature DB >> 536469

The effects of an ergot alkaloid derivative (Hydergine) on aspects of psychomotor performance, arousal, and cognitive processing ability.

I Hindmarch, A C Parrott, M Lanza.   

Abstract

Hydergine, 12 mg per day for two weeks, has some direct activity on a variety of tasks of mental and cognitive performance. These results add support to biochemical findings that implicate the ergot alkaloids (particularly co-dergo-crine, Hydergine) in cellular activity likely to increase cortical arousal and awareness. The high dose of Hydergine used in this volunteer study was exceptionally well tolerated and did produce significant results on individual measures of central nervous system activity which might suggest the use of similar doses in patient populations. The findings of a hangover of activity after drug withdrawal and the fact that some CNS activity (serial subtraction of 17s) is not obvious until two weeks of medication would suggest the need for pharmacokinetic measures to be taken in conjunction with psychologic assessments. It would seem that a two-week schedule of repeated doses is the minimum required to produce an effect on CNS activity, but even with such a dose regimen it appears that the drug continues to exert some effect after its withdrawal.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 536469     DOI: 10.1002/j.1552-4604.1979.tb01643.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  5 in total

1.  Psychiatry-important advances in clinical medicine: ergot alkaloids and dementia.

Authors:  J A Yesavage
Journal:  West J Med       Date:  1983-03

Review 2.  Psychomotor function and psychoactive drugs.

Authors:  I Hindmarch
Journal:  Br J Clin Pharmacol       Date:  1980-09       Impact factor: 4.335

Review 3.  Co-dergocrine mesylate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in age-related cognitive decline.

Authors:  A N Wadworth; P Chrisp
Journal:  Drugs Aging       Date:  1992 May-Jun       Impact factor: 3.923

4.  The effects of clobazam and lorazepam on aspects of psychomotor performance and car handling ability.

Authors:  I Hindmarch; A C Gudgeon
Journal:  Br J Clin Pharmacol       Date:  1980-08       Impact factor: 4.335

5.  Effect of Co-dergocrine mesylate on tardive dyskinesia. A preliminary report.

Authors:  J Hajioff; M Wallace
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.